ATE382332T1 - Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid - Google Patents

Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid

Info

Publication number
ATE382332T1
ATE382332T1 AT05774341T AT05774341T ATE382332T1 AT E382332 T1 ATE382332 T1 AT E382332T1 AT 05774341 T AT05774341 T AT 05774341T AT 05774341 T AT05774341 T AT 05774341T AT E382332 T1 ATE382332 T1 AT E382332T1
Authority
AT
Austria
Prior art keywords
dissolution
buffer
tamsulosin hydrochloride
controlled release
release formulation
Prior art date
Application number
AT05774341T
Other languages
English (en)
Inventor
Lech Wiackowski
Wieslaw Szelejewski
Andrzej Zaremba
Edyta Pesta-Dynda
Zofia Marchlewska-Cela
Original Assignee
Inst Farmaceutyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Farmaceutyczny filed Critical Inst Farmaceutyczny
Application granted granted Critical
Publication of ATE382332T1 publication Critical patent/ATE382332T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05774341T 2004-08-12 2005-08-12 Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid ATE382332T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL369566A PL204079B1 (pl) 2004-08-12 2004-08-12 Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania

Publications (1)

Publication Number Publication Date
ATE382332T1 true ATE382332T1 (de) 2008-01-15

Family

ID=35445840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05774341T ATE382332T1 (de) 2004-08-12 2005-08-12 Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid

Country Status (7)

Country Link
US (1) US20070298101A1 (de)
EP (1) EP1784161B1 (de)
AT (1) ATE382332T1 (de)
DE (1) DE602005004164T2 (de)
PL (2) PL204079B1 (de)
SI (1) SI1784161T1 (de)
WO (1) WO2006016829A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2854054C (en) * 2011-12-02 2020-05-12 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
US10722458B2 (en) * 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528195D0 (en) * 1985-11-15 1985-12-18 Boots Co Plc Therapeutic compositions
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
JP4019374B2 (ja) * 2001-07-27 2007-12-12 アステラス製薬株式会社 口腔内速崩壊錠用徐放性微粒子含有組成物およびその製造法
ES2256544T3 (es) * 2001-11-07 2006-07-16 Synthon B.V. Comprimidos de tamsulosina.

Also Published As

Publication number Publication date
PL1784161T3 (pl) 2008-05-30
EP1784161A1 (de) 2007-05-16
SI1784161T1 (sl) 2008-06-30
PL204079B1 (pl) 2009-12-31
DE602005004164D1 (de) 2008-02-14
EP1784161B1 (de) 2008-01-02
PL369566A1 (pl) 2006-02-20
US20070298101A1 (en) 2007-12-27
DE602005004164T2 (de) 2008-12-11
WO2006016829A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
JP6426560B2 (ja) 新規の、効力のあるタペンタドール剤形
Kranz et al. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug
CA2795324C (en) Pharmaceutical compositions comprising hydromorphone and naloxone
CA2704646C (en) Sustained-release tablets with hydromorphone
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
JP2009538918A (ja) フェニレフリンを含有する徐放薬学的投薬形態
WO2011053003A2 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
RU2333745C2 (ru) Композиции с контролируемым высвобождением
US20190054088A1 (en) Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
KR20130083903A (ko) 저장 안정성 제제를 제조하기 위한 결합제의 용도
WO2013162114A1 (ko) 위체류 약물전달 시스템을 이용한 서방성 제제
Charoo et al. Biowaiver monograph for immediate-release solid oral dosage forms: bisoprolol fumarate
KR20090015990A (ko) 페닐에프린의 지속 방출용 약제학적 조성물
Kranz et al. Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations
US20100003322A1 (en) Enteric coated hydrophobic matrix formulation
Kranz et al. Development of a multi particulate extended release formulation for ZK 811 752, a weakly basic drug
ATE382332T1 (de) Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid
US20080138411A1 (en) Modified Release Formulations Of Selective Serotonin Re-Uptake Inhibitors
KR20230080461A (ko) 약학적 제형
KR101464053B1 (ko) 4-메틸피라졸 배합물
US20150148388A1 (en) Chemical composition
US9907789B2 (en) Sustained-release preparation
WO2007015270A3 (en) Novel controlled release compositions of selective serotonin reuptake inhibitors
RU2018137590A (ru) Фармацевтические композиции для производного n-пропаргиламина
EP1628642B1 (de) Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties